China Rare Earth Resources And Technology (000831) H2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
H2 2024 earnings summary
15 Dec, 2025Executive summary
Revenue declined 24.09% year-over-year to ¥3.03 billion, with a net loss of ¥286.91 million attributable to shareholders, reversing last year's profit.
Gross margin fell to 15.75%, and basic/diluted EPS dropped to -0.2704 from 0.4229.
Cash flow from operations was negative ¥594.10 million, a sharp decrease from last year.
The company faced significant inventory write-downs and non-recurring tax payments, impacting profitability.
Financial highlights
Operating income: ¥3.03 billion, down 24.09% year-over-year.
Net loss attributable to shareholders: ¥286.91 million, compared to a profit of ¥417.67 million last year.
Gross margin: 15.75%, down 6.6 percentage points.
Cash flow from operations: -¥594.10 million, down 271.65% year-over-year.
Total assets: ¥5.49 billion, down 0.92% from year-end 2023.
Outlook and guidance
The company expects continued industry consolidation and high-quality development, with a focus on cost control, efficiency, and technological innovation.
Plans to enhance capital operations, expand resource acquisition, and strengthen R&D for high-value products.
2025 is positioned as a year for quality improvement and strategic investment, with a focus on stabilizing operations and expanding market share.
Latest events from China Rare Earth Resources And Technology
- Nine-month net profit surged 194.67% on rare earth price recovery and new production.000831
Q3 202530 Oct 2025 - Revenue up 62% and net profit turned positive on rare earth price rebound and cost reversals.000831
H1 202529 Aug 2025 - Net loss of ¥203 million on 45% lower revenue, with major share repurchase underway.000831
Q3 202413 Jun 2025 - Net loss of RMB 244 million in H1 2024 as rare earth prices and revenue declined sharply.000831
H1 202413 Jun 2025 - Net profit rebounded to 72.62 million yuan on strong revenue growth and rare earth price recovery.000831
Q1 20256 Jun 2025